Loading quotes...

Forecast

There is no analyst data available for this company.

News Go to news feed

Pharma Mar reports strong revenue and profit growth in fourth quarter 2025

Pharma Mar reported a marked financial improvement for Q4 2025: total revenue rose 27% year-on-year, EBITDA increased fivefold to around €68 million, and net income grew 187% to €75 million. Sales revenue rose 20%, license income increased 66%, and R&D spending fell 8% to €95 million. The stock rose 1.78% to €78.85 after the figures. Management plans a commercial expansion in Europe and expects short-term increases in selling costs due to the launch of Zepzelca. » More on de.investing.com
PharmaMar reports strong revenue and profit growth in 2024 driven by successful oncology development

PharmaMar increased its revenue by 11% to €174.9 million in the 2024 fiscal year and achieved a significant rise in net profit to €26.1 million. The company benefited from successful licensing agreements, a robust oncology pipeline, and positive clinical trial results, particularly for Lurbinectedin. With a solid balance sheet and clear growth strategies, PharmaMar sees itself well positioned for the future. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2026, Pharma Mar has already paid €1.00 in dividends. The last payout was in July.

Financials

In the last quarter, Pharma Mar had revenue of €54.42m and net profit of €8.14m

(EUR)	September 2026	YoY
Revenue	54.42m	52.58%
Gross profit	48.62m	55.09%
Net profit	8.14m	298.61%
EBITDA	8.57m	539.92%

Fundamentals

Metric	Value
Market capitalization	€1.13bn
Number of shares	17.34m
52-week high/low	€105.20 - €62.00
Dividend yield	1.53%
Dividends TTM	€1.00
Beta	0.47
P/E ratio	16.46
PEG ratio	0.15
P/B ratio	4.78
P/S ratio	4.78

Company profile

Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, Italy, Germany, Ireland, rest of EU, the United States, and internationally. The company operates through three segments: Oncology, Diagnostics, and RNA interference. It develops and commercializes Yondelis for the treatment of soft tissue sarcomas and for ovarian cancer; Aplidin for treating multiple myeloma; and Zepzelca for treating patients with small cell lung cancer. The company also develops PM14 which is in phase II clinical trails for the treatment of solid tumors. In addition, it develops and markets diagnostics kits; and develops drugs with therapeutic activity based on reducing or silencing gene expression. The company was incorporated in 1986 and is based in Madrid, Spain.